PF-06648671
DrugExperimental Pfizer compound which will be dosed as oral suspension, single dose at 300 mg and/or 1-2 lower doses
NCT Number: NCT02407353
This is phase 1 investigator-and-subject blind, sponsor open, randomized, placebo controlled, parallel study in healthy subjects to evaluate the pharmacodynamics effect of single oral doses of PF-06648671 on CSF Aβ concentrations using serial CSF sampling methodology.
Looking for future studies?
Notify Me18 year–55 year
All sexes
Interventional
Phase 1
California Clinical Trials Medical Group, Inc., Glendale, California, United States
This study is investigator-and-subject blind, sponsor open, randomized, placebo-controlled, parallel study in healthy subjects to evaluate central (CSF) and peripheral (plasma) pharmacodynamics effects (Abeta) over 36 hours post single doses of PF-06648671. Two cohorts will be run in sequential. the first cohort is to evaluate the Abeta effect at top dose of 300 mg PF-06648671 and second cohort is to evaluate the Abeta effect at top dose (if more subjects are required) and/or 1-2 lower doses
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Experimental Pfizer compound which will be dosed as oral suspension, single dose at 300 mg and/or 1-2 lower doses
Placebo which will be dosed as oral suspension, single doses to match PF-06648671
Time frame: 0-36 hours postdose
Time frame: 0-2 weeks
Counts of participants who have TEAEs, defined as newly occuring or worsening after first dose. Relatedness to PF-06648671 will be assessed by the investigator (Yes/No). Participants with multiple occurrence of an AE within a category will be counted once within the category
Time frame: 0-2 weeks
Measurement of supine vital signs
Time frame: 0-2 weeks
Measurement of standard 12-lead ECG (single)
Time frame: 0-72 hours postdose
Time frame: 0-72 hours postdose
Time frame: 0-72 hours postdose
Time frame: 0-72 hours postdose
Time frame: 0-72 hours postdose
Time frame: 0-72 hours postdose
Time frame: 0-72 hours postdose
Time frame: 0-36 hours postdose
Time frame: 0-36 hours postdose
Time frame: 0-36 hours postdose
Time frame: 0-36 hours postdose
Time frame: 0-72 hours postdose
Plasma Aβ40, Aβ42 and Aβtotal if possible
Time frame: 0-36 hours postdose
Time frame: 0-2 weeks
Pre-defined criteria were established for each lab test to identify potential clinical importance
Pfizer
Industry
A Phase 1 Investigator-and-subject Blind, Randomized, Placebo Controlled, Parallel Study In Healthy Subjects To Evaluate The Pharmacodynamic Effects Of Single Oral Doses Of Pf-06648671 On Aβ Concentrations In Cerebrospinal Fluid Using Serial Sampling Methodology
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07470125
Healthy Subjects
Seoul, South Korea
View Trial DetailsNCT06818032
Healthy, Healthy Adult
Burlington, Vermont, United States
View Trial DetailsNCT00761631
Healthy Subjects
Benton, Arkansas, United States
View Trial DetailsNCT02610465
Cardiac-Related Conditions, Healthy Subjects
Bethesda, Maryland, United States
View Trial Details